Search

Your search keyword '"Pavlíček, Petr"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Pavlíček, Petr" Remove constraint Author: "Pavlíček, Petr"
38 results on '"Pavlíček, Petr"'

Search Results

1. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

5. P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

6. An Analysis of the Bi-modal Size Distribution of the Coarse Droplets in a Steam Turbine

8. Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

9. 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group

10. Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data

12. P-210: Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: phase 2 study interim analysis (IA)

13. OAB-046: COVID-19 infection in multiple myeloma patients – retrospective analysis of 371 Czech patients

15. Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

16. P-159 Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients - real world evidence

17. Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model

18. The Reynolds number effect on dynamics of the wake behind a circular cylinder

19. P-177: Outcomes in risk-stratified patients with smoldering multiple myeloma: a retrospective analysis of real-world data from the Czech Registry of Monoclonal Gammopathies

20. An Experimental Study of the Coarse Droplets Formation.

21. Experimental equipment for an electrical resistance tomography of a gas lift flow

24. Comfort parameters – Ventilation of a subway wagon

25. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

26. Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients

28. Creation of humour in plays Antonin Prochazka 'Pilsen Moliere'

29. Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

31. Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma

32. Urine immunofixation is not necessary for CR definition in myeloma patients with complete M protein molecule

33. Management of urban forests

34. Multicentered patient‐based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse

35. Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population

36. Bortezomib (Velcade) in the Treatment of Relapsed or Refractory Multiple Myeloma: Analysis of Safety and Efficacy of Bortezomib From Registry of Monoclonal Gammopathy of Czech Myeloma Group

38. Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation.

Catalog

Books, media, physical & digital resources